Patients aged 2-21 receiving apitegromab showed clinically meaningful motor function improvements, with a favorable safety ...

A first-in-class anti-CD19 B-cell depleting agent was safe and demonstrated superior efficacy vs placebo in patients with ...

Johnson & Johnson announces positive results from phase 2/3 Vibrance-MG study of nipocalimab in adolescents living with generalized myasthenia gravis: Savannah, Georgia Thursday, ...

Two genes were shown to be significantly associated with higher prevalence of myasthenia gravis (MG), a relatively rare autoimmune disease.

The investigational monoclonal antibody nipocalimab is associated with significant improvement in patients with generalized ...

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A ...

Johnson & Johnson has announced positive Phase II/III trial results for nipocalimab in generalized myasthenia gravis (gMG). The drug showed significant IgG reduction and sustained disease control.

Investigational nipocalimab lessened disease severity in generalized myasthenia gravis (gMG), the phase III Vivacity-MG3 ...

Myasthenia gravis (MG) is an antibody-mediated chronic neuromuscular disorder leading to fluctuating weakness and early muscle fatigue, with limited treatment options available. In MG, such as other ...

"Inebilizumab is a humanized monoclonal antibody that causes targeted and sustained depletion of CD19-positive B cells, ...